Prakash Radhakrishnan
Overview
Explore the profile of Prakash Radhakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mack K, Bauer D, Carter L, Carrasco S, Atmane M, Viray T, et al.
Nucl Med Biol
. 2024 Nov;
140-141:108976.
PMID: 39615062
Background: Peritoneal metastasis with micrometastatic cell clusters is a common feature of advanced ovarian cancer. Targeted alpha therapy (TAT) is an attractive approach for treating micrometastatic diseases as alpha particles...
2.
Turabi K, Klute K, Radhakrishnan P
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001494
Circulating tumor DNA (ctDNA), a fragment of tumor DNA found in the bloodstream, has emerged as a revolutionary tool in cancer management. This review delves into the biology of ctDNA,...
3.
Mack K, Samuels Z, Carter L, Viray T, Mandleywala K, Brooks C, et al.
J Nucl Med
. 2024 Mar;
65(4):580-585.
PMID: 38485271
Aberrantly expressed glycans on mucins such as mucin-16 (MUC16) are implicated in the biology that promotes ovarian cancer (OC) malignancy. Here, we investigated the theranostic potential of a humanized antibody,...
4.
Aguilar E, Sagar S, Murray B, Rajesh C, Lei E, Michaud S, et al.
Mol Cancer Ther
. 2024 Feb;
23(6):836-853.
PMID: 38394685
Mucin-16 (MUC16) is a target for antibody-mediated immunotherapy in pancreatic ductal adenocarcinoma (PDAC) among other malignancies. The MUC16-specific monoclonal antibody AR9.6 has shown promise for PDAC immunotherapy and imaging. Here,...
5.
Muilenburg K, Isder C, Radhakrishnan P, Batra S, Ly Q, Carlson M, et al.
Cancer Lett
. 2023 Mar;
561:216150.
PMID: 36997106
Pancreatic cancer is difficult to resect due to its unique challenges, often leading to incomplete tumor resections. Fluorescence-guided surgery (FGS), also known as intraoperative molecular imaging and optical surgical navigation,...
6.
Rajesh C, Radhakrishnan P
Front Oncol
. 2023 Jan;
12:1093496.
PMID: 36686742
Cellular signaling pathways are intricately regulated to maintain homeostasis. During cancer progression, these mechanisms are manipulated to become harmful. O-glycosylation, a crucial post-translational modification, is one such pathway that can...
7.
Rajesh C, Sagar S, Rathinavel A, Chemparathy D, Peng X, Yeh J, et al.
Int J Mol Sci
. 2022 May;
23(10).
PMID: 35628269
Elevated levels of Mucin-16 (MUC16) in conjunction with a high expression of truncated O-glycans is implicated in playing crucial roles in the malignancy of pancreatic ductal adenocarcinoma (PDAC). However, the...
8.
Struble L, Smith A, Lutz W, Grubbs G, Sagar S, Bayles K, et al.
Protein Sci
. 2022 Apr;
31(5):e4300.
PMID: 35481636
The COVID-19 pandemic caused by SARS-CoV-2 infection has led to socio-economic shutdowns and the loss of over 5 million lives worldwide. There is a need for the identification of therapeutic...
9.
Napoleon J, Sagar S, Kubica S, Boghean L, Kour S, King H, et al.
Proc Natl Acad Sci U S A
. 2022 Apr;
119(18):e2115071119.
PMID: 35476515
Activation of inhibitor of nuclear factor NF-κB kinase subunit-β (IKKβ), characterized by phosphorylation of activation loop serine residues 177 and 181, has been implicated in the early onset of cancer....
10.
Sharma S, Mack K, Piersigilli A, Pourat J, Edwards K, Keinanen O, et al.
Clin Cancer Res
. 2021 Dec;
28(5):948-959.
PMID: 34907079
Purpose: Advances in our understanding of the contribution of aberrant glycosylation to the pro-oncogenic signaling and metastasis of tumor cells have reinvigorated the development of mucin-targeted therapies. Here, we validate...